<DOC>
	<DOCNO>NCT00734318</DOCNO>
	<brief_summary>The study compare efficacy safety FlutiForm® v Flixotide® plus Foradil® treatment severe persisent asthma adult subject .</brief_summary>
	<brief_title>Study FlutiForm® Versus Fluticasone Plus Formoterol Adult Subjects With Severe Asthma</brief_title>
	<detailed_description>This study involve 2 week run-in phase follow 8 week double blind treatment phase . During run-in phase , subject receive Flixotide® . In treatment phase subject randomise one four treatment group receive either high dose FlutiForm® Foradil® plus Flixotide® placebo low dose FlutiForm® plus Foradil® Flixotide® placebo Foradil® plus Flixotide® FlutiForm® placebo Flixotide® FlutiForm® plus Foradil® placebo . Efficacy assess lung function test , asthma symptom , sleep disturbance due asthma rescue medication use . Safety assess adverse event , lab test , ECGs vital sign .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female subject least 18 year old . 2 . Females less one year postmenopausal must negative urine pregnancy test record screen visit prior first dose study medication , nonlactating , willing use adequate highly effective method contraception throughout study . A highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly sterilisation , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner . 3 . Known history severe persistent , reversible asthma ≥ 6 month prior Screening Visit characterise treatment ICS dose ≥ 500µg fluticasone equivalent . 4 . Demonstrated FEV1 ≥ 40 % ≤ 80 % predict normal value ( Quanjer et al. , 1993 ) Screening Visit ( Visit 1 ) Randomisation Visit ( Visit 3 ) follow appropriate withhold asthma medication ( applicable ) . No β2agonist use day screen . No use inhale combination asthma therapy day screen . Inhaled corticosteroid allow day screen . 5 . Documented reversibility ≥ 15 % FEV1 screening phase . 6 . Demonstrated satisfactory technique use study medication . 7 . Willing able enter information electronic diary attend study visit . 8 . Willing able substitute study medication pre study prescribe asthma medication duration study . 9 . Written inform consent obtain . Inclusion criterion require follow runin : 10 . Subject use rescue medication least 3 day AND least one night sleep disturbance ( i.e. , sleep disturbance score ≥ 1 ) OR least 3 day asthma symptom ( i.e. , symptom score ≥ 1 ) last 7 day runin period . Exclusion criterion : 1 . Near fatal lifethreatening ( include intubation ) asthma within past year . 2 . Hospitalisation emergency visit asthma within 4 week screen visit . 3 . Known history systemic ( injectable oral ) corticosteroid medication within 1 month Screening Visit . 4 . Known history omalizumab use within past 6 month . 5 . Current evidence know history clinically significant disease abnormality include uncontrolled coronary artery disease , congestive heart failure , myocardial infarction , cardiac dysrhythmia . 'Clinically significant ' defined disease , opinion Investigator , would put subject risk study participation , would affect outcome study . 6 . In investigator 's opinion clinically significant upper low respiratory infection within 4 week prior Screening Visit . 7 . Significant , nonreversible , active pulmonary disease ( e.g. , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , bronchiectasis , tuberculosis ) . 8 . Known Human Immunodeficiency Virus ( HIV ) positive status . 9 . Subject smoke history equivalent `` 10 pack year '' ( i.e. , least 1 pack 20 cigarette /day 10 year 10 packs/day 1 year , etc. ) . 10 . Current smoke history within 12 month prior Screening Visit . 11 . Current evidence know history alcohol and/or substance abuse within 12 month prior Screening Visit . 12 . Subject take Bblocking agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole ( Hismanal ) , quinidine type antiarrhythmic , potent CYP 3A4 inhibitor ketoconazole within past week . 13 . Current use medication allow protocol effect bronchospasm and/or pulmonary function . 14 . Current evidence know history hypersensitivity idiosyncratic reaction test medication component . 15 . Subject recieved investigational drug within 30 day Screening Visit ( 12 week oral injectable steroid ) . 16 . Subject currently participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Severe asthma</keyword>
	<keyword>Fluticasone</keyword>
	<keyword>Formoterol</keyword>
</DOC>